VJHemOnc is committed to improving our service to you

ASH 2018 | Effective immunomodulation with pomalidomide during induction TST for AML and MDS

VJHemOnc is committed to improving our service to you

Joshua Zeidner

Joshua Zeidner, MD, of the UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, discusses the results of the Phase I dose escalation study (NCT02029950) assessing the safety and tolerability of pomalidomide administration after induction timed sequential therapy (TST) in newly diagnosed patients with acute myeloid leukemia (AML) or high-risk myelodysplasia (MDS). Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Zeidner reveals that pomalidomide can be added at the time of early lymphocyte recovery (ELR) after induction TST without increased toxicity and with favourable response rates compared with previous controls.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter